Second Line Therapy in Advanced Biliary Tract Cancer

Biliary Tract Cancer Clinical Trial

— BIT-2  

Official title:

A Randomized Phase II Trial of Second Line Therapy in Advanced Biliary Tract Cancer: Capecitabine or Capecitabine Plus Mitomycin C

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01530503
• Other study ID #: 2011-002002-70
• Status: Completed
• Phase: Phase 2
• First received: February 3, 2012
• Last updated: February 24, 2016
• Start date: November 2011
• Est. completion date: October 2013

Study information

• Verified date: February 2016
• Source: IRCCS San Raffaele
• Contact: n/a
• Is FDA regulated: No
• Health authority: Italy: National Institute of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the therapeutic activity of capecitabine alone or in combination with mitomycin C as second-line therapy in patients with advanced/metastatic biliary adenocarcinoma in progression after gemcitabine and platinum compounds

Description:

Biliary tract adenocarcinoma is an uncommon tumor with a poor prognosis and a median overall survival (OS) rarely exceeding 6 months. Less than 25% of patients are resectable at diagnosis and, even in this subset of patients, relapse rate is high. An improvement of OS and quality of life for patients receiving chemotherapy versus best supportive care was demonstrated in advanced disease. Recently, cisplatin and gemcitabine combination was identified as the new standard first-line chemotherapy, yielding a median progression free survival (PFS) and median OS of 8.5 and 11.7 months, respectively. Despite the outcome improvement, disease progression is a constant and approximately half of patients failing upfront treatment has a good performance status and are willing to undergo further treatment. No standard salvage chemotherapy regimen has been identified. Clinical trials are difficult to perform due to the rarity and heterogeneity of these tumors and to the lack of interest of the pharmaceutical industry. Fluoropyrimidines and mitomycin C have been considered the basis of palliative chemotherapy for a long time. The investigators decided to explore the activity, in terms of PFS, of capecitabine alone or combined with mitomycin C as second-line therapy in patients with pathological diagnosis of advanced biliary tract cancer and progressive disease after gemcitabine and cisplatin, by means of an open label randomized multicentric phase II trial.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 52
• Est. completion date: October 2013
• Est. primary completion date: October 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Signed and dated IRB/IEC-approved Informed Consent.

2. Cytological or histological diagnosis of locally advanced or metastatic adenocarcinoma of the biliary tract (Ampulla of Vater, gallbladder, intra or extra-hepatic biliary ducts).

3. Disease progressing after first-line chemotherapy with gemcitabine and platinum analogs (only one prior systemic therapy allowed).

4. Age 18-75 years

5. Karnofsky Performance Status > 50%

6. Estimated life expectancy of at least 3 months.

7. Negative pregnancy test (if female in reproductive years).

8. Adequate bone marrow, liver and kidney function: leukocyte > 3500/mm3; absolute neutrophil count (ANC) > 1500/mm3; platelet count > 100000/mm3; hemoglobin > 10 g/dl; creatinine < 1.5 mg/dL; total bilirubin = 1.5 x upper limit of normal range (ULN); SGOT e SGPT = 2.5 ULN

9. At the time of start of treatment, at least 2 weeks must have elapsed since completion of prior chemotherapy, minor surgery and radiotherapy (provided that no more than 25% of bone marrow reserve has been irradiated).

10. Resolution of all acute toxic effects of any prior chemotherapy, surgery or radiotherapy to NCI CTC (Version 4.03) grade = 1 for hematologic toxicities and = 2 for non hematologic toxicities, with the exception of alopecia.

11. Able and willing to comply with scheduled visits, therapy plans, and laboratory tests required in this protocol.

Exclusion Criteria:

1. Previous or concurrent malignancies at other sites with the exception of surgically cured carcinoma in-site of the cervix and basal or squamous cell carcinoma of the skin and of other neoplasm without evidence of disease at least from 5 years.

2. Known brain metastases.

3. Previous second-line or adjuvant treatment.

4. Concurrent treatment with other experimental drugs.

5. Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, cardiac arrhythmia) =1 year prior to dosing.

6. Clinically significant disease including: Cerebral Vascular Accident; other serious underlying medical condition(s) which could impair the ability of the patient to participate in the study.

7. History of interstitial lung disease (eg, pneumonia or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest CT scan

8. Known positive tests for human immunodeficiency virus (HIV) infection, active hepatitis B or hepatitis C

9. Subject who is pregnant or breast feeding

10. Woman or man of child-bearing potential not consenting to use adequate contraceptive precautions ie. double barrier contraceptive methods (e.g., diaphragm plus condom), or abstinence during the course of the study and for 6 months after the last study drug administration for women, and 1 month for men

11. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Biliary Tract Cancer
• Biliary Tract Neoplasms

Intervention

Drug:
• capecitabine and mitomycin
oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion mitomycin C 6 mg/m2 day 1. Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months
• Capecitabine
oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food. Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months

Locations

Country	Name	City	State
Italy	Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G Salesi	Ancona
Italy	A.O. Ospedali Riuniti	Bergamo
Italy	Azienda Ospedaliero-Universitaria Policlinico S. Orsola-Malpighi	Bologna
Italy	Fondazione Piemontese Per la Ricerca sul Cancro	Candiolo (Torino)
Italy	Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi	Catania
Italy	Fondazione Istituto San Raffaele G. Giglio	Cefalù	Palermo
Italy	ASUR zona territoriale N. 6 FABRIANO	Fabriano	Ancona
Italy	Ospedale San Raffaele	Milan
Italy	Istituto Oncologico Veneto I.R.C.C.S.	Padova
Italy	Azienda Ospedaliero-Universitaria Pisana	Pisa
Italy	Azienda Ospedaliera Regionale San Carlo	Potenza
Italy	Istituto Nazionale dei Tumori Regina Elena	Roma
Italy	Ospedale Generale Provinciale	Saronno (VA)
Italy	Azienda Ospedaliera Universitaria San Giovanni Battista di Torino	Torino
Italy	Azienda Ospedaliero Universitaria Santa Maria della Misericordia	Udine
Italy	Azienda Ospedaliera Universitaria Integrata	Verona

Sponsors (2)

Lead Sponsor	Collaborator
IRCCS San Raffaele	Regione Lombardia

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival (PFS)	This is a multi-centre phase II, randomized study. Patients will be stratified based on disease site and stage. For the purpose of the study, PFS-6 rate will be considered the primary outcome measure. The maximum PFS-6 rate of low clinical interest is 15% and the minimum PFS-6 rate of interest is set to 35%. The target enrollment, using a type I error of 5% and a test power of 90%, will be estimated to be 26 patients per treatment arm. The regimen will be considered active if at least 8 out of first 26 evaluable patients are PFS-6.	6 month PFS	Yes
Secondary	Overall Survival (OS)	the time from the date of randomization to the date of death from any cause; All patients will be followed for survival every 3 months up to 2 years after the end of treatment	median OS (up to 2 years)	Yes